JonesTrading analyst Boris Peaker has maintained their bullish stance on JANX stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Boris Peaker has given his Buy rating due to a combination of factors related to Janux Therapeutics’ clinical pipeline and current valuation. He highlights multiple near- and medium-term catalysts, including upcoming Phase I readouts for JANX007 in metastatic castration-resistant prostate cancer and an initial clinical update for JANX011, as well as the planned start of clinical development for JANX013 and continued progress with JANX014.
He also points out that Janux’s shares are trading around a zero or even negative enterprise value, suggesting that expectations embedded in the stock are extremely low. In his view, any favorable data on safety, especially better management of cytokine release syndrome, and signs of more durable responses in earlier-line patients could drive a sharp re-rating of the stock, and when combined with a strong cash position relative to projected burn, this creates an appealing risk/reward setup for investors.
According to TipRanks, Peaker is a 5-star analyst with an average return of 19.6% and a 45.36% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Janux Therapeutics Inc, and OnKure Therapeutics.